Why the study?
Does low-dose C-type natriuretic peptide combined with ultrasound and microbubbles prevent neointimal formation in a rat carotid artery-balloon injury model?
Does low-dose C-type natriuretic peptide combined with ultrasound and microbubbles prevent neointimal formation in a rat carotid artery-balloon injury model?
Answers are grounded in this paper and cite their sources.
Ultrasound and microbubbles enhance the efficacy of short-term, low-dose C-type natriuretic peptide infusion in preventing neointimal formation after vascular injury in rats.
OBJECTIVES: Long-term intravenous infusion of high-dose C-type natriuretic peptide (CNP) is known to prevent neointimal formation after vascular injury. Ultrasound (US) irradiation during microbubbles (MBs) infusion (US/MBs) has been used for local delivery of bioactive agents. We examined whether short-term infusion of CNP could also inhibit neointimal development and whether combined US/MBs treatment at the beginning of the CNP infusion could enhance its effect. METHODS: In the rat carotid artery-balloon injury model, the intima/media area (I/M) ratio 14 days after injury was compared among various short-term post-injury treatments. For combined US/MBs, a commercial echocardiograph (1.8 MHz, mechanical index 1.0) and albumin-coated octafluoropropane gas MBs were used. RESULTS: Infusion of high-dose CNP (1.0 microg/kg/min) immediately after injury for only 24 h successfully reduced the I/M ratio (0.18+/-0.05) to 18% of the ratio in control rats (1.00+/-0.13) that underwent only balloon injury. Although low-dose CNP (0.1 microg/kg/min for 24 h) alone was not effective in reducing the I/M ratio (0.83+/-0.18), combined US/MBs treatment for the first 80 min of the infusion markedly reduced the I/M ratio (0.17+/-0.07), which persisted until 28 days after injury (0.16+/-0.04). CONCLUSIONS: The effects of CNP on the events occurring early after arterial injury may be important in preventing subsequent neointimal development. Thus, intravenous infusion of CNP with US/MBs at its initiation may provide a clinically feasible anti-restenosis therapy applicable immediately after vascular interventions.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: